Epidemiological and Economic Evaluation of a Pilot Prostate Cancer Screening Program
Table 6
Prostate cancer screening costs in the Pavlodar region in 2017.
Stages/year
1 Stage of screening
2 Stage of screening
3 Stage of screening
4 Stage of screening
Total KZT (thousand)
Number of target patients aged 50, 54, 58, 62, 66 for total PSA
Sum per 1 patient, KZT
Total sum, KZT (thousand)
Number of patients for free & ProPSA (4%)
Sum per 1 patient, KZT
Total sum, KZT (thousand)
Number of patients for biopsy (3%)
Sum per 1 patient, KZT
Total sum, KZT (thousand)
Number of patients for histology (3%)
Sum per 1 patient, KZT
Total sum, KZT (thousand)
Total
9638
1323,42
12755
145
27625,05
4006
145
6561,0
951
145
2348,7
2724
20437
-value
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
1 Stage
9638
1323,42
12755
12755,1
Venous blood sampling
9638
134,02
1292
1291,7
Total PSA levels testing
9638
1189,4
11463
11463,4
2 Stage
145
27625,05
4006
4005,6
Total PSA levels testing
145
1189,4
172
172,5
Free PSA levels testing
145
2091,05
303
303,2
Pro-PSA levels testing
145
24344,6
3530
3530,0
3 Stage
145
6561,00
951
951,3
Urologist consultation
145
770,85
112
111,8
Transrectal Ultrasonography of the Prostate
145
673,71
98
97,7
Prostate Biopsy
145
5116,44
742
741,9
4 Stage
145
2348,67
2724
2724,5
Histological evaluation
145
2348,67
2724
2724,5
test of difference. ANOVA. The chi square test is only valid for comparing the number of patients at the first stage of screening with subsequent screening stages. We did not compare the subsequent screening stages between each other as these are the same observations.